New treatments for mitochondrial disease-no time to drop our standards. - Wikidata - awgldk - TriplyDB

New treatments for mitochondrial disease-no time to drop our standards.

New treatments for mitochondrial disease-no time to drop our standards.

http://www.wikidata.org/entity/Q37140299

about

Genetic manipulation for inherited neurodegenerative diseases: myth or reality?Mitochondrial disorders in children: toward development of small-molecule treatment strategies Mitochondrial disease in adults: what's old and what's new?Mitochondrial targets for pharmacological intervention in human disease Leber hereditary optic neuropathy: current perspectives A neurodegenerative perspective on mitochondrial optic neuropathies Toward a therapy for mitochondrial disease Mitochondria: Much ado about nothing? How dangerous is reactive oxygen species production?Is 2D speckle tracking echocardiography useful for detecting and monitoring myocardial dysfunction in adult m.3243A>G carriers? - a retrospective pilot study Treatment strategies for inherited optic neuropathies: past, present and future Treatment of mitochondrial disorders.Medical management of hereditary optic neuropathies.Mitochondrial DNA: impacting central and peripheral nervous systems.2-deoxy-D-glucose enhances anesthetic effects in mice Mitochondrial vulnerability and increased susceptibility to nutrient-induced cytotoxicity in fibroblasts from leigh syndrome French canadian patients.Urinary ATP Synthase Subunit β Is a Novel Biomarker of Renal Mitochondrial Dysfunction in Acute Kidney Injury.Transcriptome analysis of complex I-deficient patients reveals distinct expression programs for subunits and assembly factors of the oxidative phosphorylation system.Reduced Glucose Sensation Can Increase the Fitness of Saccharomyces cerevisiae Lacking Mitochondrial DNA.Mitochondrial Diseases Part III: Therapeutic interventions in mouse models of OXPHOS deficiencies.Serum GDF15 Levels Correlate to Mitochondrial Disease Severity and Myocardial Strain, but Not to Disease Progression in Adult m.3243A>G Carriers.A Metabolic Signature of Mitochondrial Dysfunction Revealed through a Monogenic Form of Leigh Syndrome Loss of apoptosis-inducing factor critically affects MIA40 function.Evaluating Harms in the Assessment of Net Benefit: A Framework for Newborn Screening Condition Review.Emerging therapies for mitochondrial disorders.Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society.Mitochondrial diseases: advances and issues.The Effect of Mitochondrial Supplements on Mitochondrial Activity in Children with Autism Spectrum Disorder.Bioenergetic medicine.Syndromes associated with mitochondrial DNA depletion.Mitochondrially targeted ZFNs for selective degradation of pathogenic mitochondrial genomes bearing large-scale deletions or point mutations.Mitochondrial dysfunction in central nervous system white matter disorders.The spectrum of pyruvate oxidation defects in the diagnosis of mitochondrial disorders.Treatment options for lactic acidosis and metabolic crisis in children with mitochondrial disease.Hospitalizations for mitochondrial disease across the lifespan in the U.S.Pharmacologic modeling of primary mitochondrial respiratory chain dysfunction in zebrafish.Bromodomain Inhibitors Correct Bioenergetic Deficiency Caused by Mitochondrial Disease Complex I Mutations Mitochondrial Neurogastrointestinal Encephalomyopathy Caused by Thymidine Phosphorylase Enzyme Deficiency: From Pathogenesis to Emerging Therapeutic Options.Domains of Daily Physical Activity in Children with Mitochondrial Disease: A 3D Accelerometry Approach.Nutritional interventions in primary mitochondrial disorders: Developing an evidence base.Characterization of clinically identified mutations in NDUFV1, the flavin-binding subunit of respiratory complex I, using a yeast model system.

P2860

Q26752831-E7530E4E-1C74-40CD-9512-A1EE174101EC Q26767327-DB8C99EA-A81B-4ECD-80A2-D4DFC9B646E2 Q26776417-3EAC66A5-9D04-44DD-B2C2-6A1BCEA25F3A Q26824514-7A30B133-BE86-462C-A3E5-558E3C2867B7 Q26863599-780BAC2B-5C1D-4577-9125-940711A973B6 Q28072026-625FE21A-14C2-4280-851B-0CE9D65F5161 Q28080024-AAC18FA8-D571-4ADC-A3A5-E6223350C8E7 Q28084963-16F7CC38-62EC-4357-B4F9-E3DA5DBE01C8 Q30362604-35EEC45F-DEDC-4288-84FC-156B1E007623 Q33595163-2AD56D50-A345-46DC-BE1B-1C2C2B39D057 Q33794684-C66C7418-4C80-4445-B5A7-40A22B89EA56 Q33980183-0B52138B-1E43-4026-BAE8-EC83C34D0F7E Q34737643-F74A5F96-C8D2-48AB-9061-7974159323EC Q34995651-C943A7FD-C909-4BA9-B630-1EF058B0D14F Q35250813-06B08411-9CAB-4539-AE68-C6F3E9A966D7 Q35535441-E8241940-462C-4129-859C-C19FD1BC5146 Q35775042-A7453241-B0F8-4C0B-B3D9-DFAC9AFFDCF2 Q35890030-7E767DD8-9050-4641-A2E0-76E94E5D1078 Q35893619-97E47C0E-5DA1-4426-A566-2CA790A63492 Q36090550-86D3BDF5-E937-45E2-884B-11E1FDCAB124 Q36279066-BC1C2061-D659-4477-A657-589BE702E664 Q36293830-EF6FC2C5-6CE9-4A24-B936-FB58CD80C583 Q36762922-F8C55FD9-AE04-4E36-98E3-FC8879F0D43F Q36967723-9AB1579F-0512-4517-A39C-CFD3E43FDEFF Q37210464-17797C5B-ECA6-4C51-8C3A-338682C3E912 Q37653002-1C666377-253D-497F-B701-BD392B3AC454 Q37676044-9DF928F8-4938-47EA-96FD-F394650F1DF4 Q37686246-03FB43C2-8156-453C-A4CB-07BF1BE33BE9 Q37701180-0A1567E1-79D6-49FF-853D-3D71EFE2E480 Q37710809-E0540FCB-C9DB-49D3-B70B-E4B6D618A10B Q38215315-DB625712-34C5-400C-B9E0-14478FFD0A10 Q38294904-A36F1D4F-6EA0-4DFE-9BD1-DD2423B302F6 Q38357534-EA1366AC-777E-494C-B6F7-34A70A6C60B4 Q38401402-449B4753-A3B9-4B33-BD25-38F0A5850F87 Q38653585-D96A4466-7922-42DC-B47F-727C74E404FE Q38743834-F1930476-FC3D-4731-A5F4-EE6B17F26893 Q38750535-6D10C4AA-1F77-409D-A5B2-932C09D64CB2 Q38769996-E46F6BF8-4FAF-4CAA-BE74-7D57D189867F Q38963725-6325E753-E1E8-41EF-A6EE-9C8580BB4A9F Q38966678-B68C767A-D423-47F0-A4DD-C2E5CE43EB2E

P2860

New treatments for mitochondrial disease-no time to drop our standards.

http://www.wikidata.org/entity/Q37140299

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

New treatments for mitochondrial disease-no time to drop our standards.

@en

New treatments for mitochondrial disease-no time to drop our standards.

@nl

type

label

New treatments for mitochondrial disease-no time to drop our standards.

@en

New treatments for mitochondrial disease-no time to drop our standards.

@nl

prefLabel

New treatments for mitochondrial disease-no time to drop our standards.

@en

New treatments for mitochondrial disease-no time to drop our standards.

@nl

P1433

Q37140299-06EAAEA0-F2B2-4C02-B450-ADBEB141DEC3

P1476

Q37140299-B6E545E6-D72F-4305-92D3-270899691A47

P2093

Q37140299-08CE48E9-C17F-4FFA-B942-70B7F06EB3AC

Q37140299-3A1249FE-CF26-45FE-8894-8A95149A44E0

Q37140299-4E867DC0-FBB2-4A9E-BA20-24A00B414070

Q37140299-5EB9E786-83D8-407A-8344-23BFFA487BA6

Q37140299-5F9C96E6-9A5A-4525-BE0C-1803E900DECC

Q37140299-6459A317-9E6F-4FC4-A5F8-B7A28523DA12

Q37140299-6D7C063A-9D87-4D2E-9A43-35AFD99ED959

Q37140299-9DE9D703-466B-4447-AA1D-7AD2699DDD17

Q37140299-A5FE933A-BE1B-44A2-B6FA-A36F28E84AE4

Q37140299-BAE4B8D9-325D-4B5F-9E34-4E8C74314B71

P2860

Q37140299-0127DFD9-D14E-4C6A-AFA3-377E023E6611

Q37140299-13A9B8CC-A73F-4BA1-A8C6-8D25CFF3D714

Q37140299-16790294-4D0F-4ED6-8240-F03181E9672C

Q37140299-18F353FC-74FF-41BC-B435-D6C086348168

Q37140299-1D8D75DE-F88B-449B-83E7-F9BD8A6654A0

Q37140299-1F4FF7EB-491A-4E32-9ABF-C95FF128EF23

Q37140299-237EDE45-0034-4C73-9833-15CE05D423AF

Q37140299-23DABEFD-3D3C-48B1-BF2E-D314A4CFF40C

Q37140299-263C0BC7-70B3-4398-9E61-5CB4940243BE

Q37140299-28098BA2-28A6-419A-940C-EC2A51277ADA

P2888

Q37140299-69E56826-E954-492A-BD95-BEDD97BB5B5E

P304

Q37140299-D06547D4-9101-42A0-B94B-7C22265FDAAB

P31

Q37140299-CEAFD97E-DB07-41C2-937C-7F0A99E82646

P356

Q37140299-A8533645-F5D3-4D0A-8CBE-D18B5F4E7156

P407

Q37140299-78BDB293-6F1C-4009-B5C0-88D74C13A8F8

P433

Q37140299-749C7492-B5F5-48D1-98CC-3C9AC15341F2

P478

Q37140299-CF16FD04-B3EE-469A-B738-E38315BDB9B7

P50

Q37140299-3AE7F01D-F057-46B0-8CA6-9A814460E133

Q37140299-431F32C7-F46D-4513-9482-1A0F7E77585E

Q37140299-4EB6E79E-34A8-4233-9C77-13998585DA2C

Q37140299-6CE51959-21E8-4FA5-BE44-4BB5C5019B81

Q37140299-92CE87D5-BE15-45E5-8078-AEF83EEB5AEF

Q37140299-B66F738A-25D1-4AE5-A59D-A06DD2AF7028

Q37140299-DC096D71-321B-4308-9172-3E22DE2FA065

P577

Q37140299-57923C27-D45E-4352-B5A6-EA8B64C25DAD

P5875

Q37140299-E4633DC5-87B9-4497-BC38-2EA03218DC3E

P698

Q37140299-0EE63787-F711-4103-A062-942F6A362B4D

P921

Q37140299-5C103D3E-EE65-499E-84D4-7070FCF866F7

P932

Q37140299-75FBD9A1-CF33-4593-B2E8-C9E1EF144D75

P356

NRNEUROL.2013.129

P1433

Nature Reviews Neurology

P1476

New treatments for mitochondrial disease-no time to drop our standards.

@en

P2093

Anu Suomalainen

http://www.w3.org/2001/XMLSchema#string

Douglas M Turnbull

http://www.w3.org/2001/XMLSchema#string

Jan Smeitink

http://www.w3.org/2001/XMLSchema#string

Kari Majamaa

http://www.w3.org/2001/XMLSchema#string

Michael Hanna

http://www.w3.org/2001/XMLSchema#string

Michio Hirano

http://www.w3.org/2001/XMLSchema#string

Robert McFarland

http://www.w3.org/2001/XMLSchema#string

Saskia Koene

http://www.w3.org/2001/XMLSchema#string

Thomas Klopstock

http://www.w3.org/2001/XMLSchema#string

Vamsi K Mootha

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment for mitochondrial disorders

Antioxidants and other pharmacological treatments for Friedreich ataxia

The creatine kinase system and pleiotropic effects of creatine

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children

Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders

Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial

31P NMR study of improvement in oxidative phosphorylation by vitamins K3 and C in a patient with a defect in electron transport at complex III in skeletal muscle.

Do idebenone and vitamin therapy shorten the time to achieve visual recovery in Leber hereditary optic neuropathy?

The effect of short-term dimethylglycine treatment on oxygen consumption in cytochrome oxidase deficiency: a double-blind randomized crossover clinical trial.

P2888

nrneurol.2013.129

P304

474-481

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRNEUROL.2013.129

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Massimo Zeviani

Patrick Yu-Wai-Man

Laurence Bindoff

Valerio Carelli

Patrick F. Chinnery

P577

2013-07-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

244481517

http://www.w3.org/2001/XMLSchema#string

P698

23817350

http://www.w3.org/2001/XMLSchema#string

P921

P932

4967498

http://www.w3.org/2001/XMLSchema#string